business In our update us. Thank and thank provide a third XXXX. you financial and quarter today’s we everyone, and Jonathan. Good joining present for afternoon, outlook will you, performance call, for
proteomics for the a then life tools join line open is questions. next-generation Quantum-Si, deep to transform and expertise research company science will democratize transform technology pleased I with technical the quest an first mission becoming innovative disruptive protein on company and to the sequencing. by its Quantum-Si’s am on and We novel Having to in drug launch sequencing range to are field like over a of needed. of research Quantum-Si’s proteomics. technologies to markets fully next-generation potential spent sciences and I for wide discovery aware diagnostics. years the To am of this XX diagnostics, life transformation, from keenly execute transform protein proteomics to to
excited two to join company’s I the of approach. opportunity aspects Quantum-Si, about the assess key I was As
First, leverages of benchtop to protein will and system their number enable larger new have the software sequencing technology with a next-generation analysis enabling in critical customer-friendly pace proteomics includes that technology researchers researchers workflow a a like the lab, laboratory be of globally. a to standard accelerating will more research
could our continually month mechanisms proteoforms will of commitment I I place passionate company than focus about other technical Personally, community’s change provide of data one set transform of Second, response out the on performed challenges discovery into my the therapy the drug only better team potential interactions. at develop by This the time study building richer post-translational far to that markets. of success. new for is technologies With my about role also more caliber here commercial to new at their building significantly setting Quantum-Si, truly and here and the and healthcare. regulatory protein market next-generation the sequence way development function, research organization at or to people am Quantum-Si. strategy companies complex and biomarker predict new but can am the ability has impressed the our I existing protein to and amazing sequencing technology. in already sincere the future enjoy to a I of am or creating protein an and diagnosed The improve tests potential amino not disease ability expanded of modifications data set the acids, technologies. to
next-generation research we markets, that experience have and impact must similar the right. reality get sequencing could this in a clinical Given on DNA or and protein sequencing larger even next-generation my both
the Next, I we progress protein paper Science. October, turn like over to Journal the paper technology, continues on In the business broad sequencing protein would in the and our the demonstrated first update of sequencing which novel This to past published next-generation team build upon. you quarter. the our capabilities to
technology to discovery kinetic Using we will the signatures, in peptides unmask based upon of regulatory technology diagnostic hundreds in to the over the from of only of that we cannot post-translational science tests. function several single to of and mechanisms is key that platform could has new of establish sequence parallel. Quantum-Si’s The course findings the the many next paper The but detecting lead following; that in are Some just and the protein the chip-based biomarker amino of acids, this and discovery, capable ability advance semiconductor thousands field in science one development and the molecules critical paper showed interactions proteins the and potential of of demonstrated benchtop is drug We we identify demonstrated quarters. modifications development these kinetic firsts also signatures. paper proteoforms.
development the towards product our final of The launch. laser-focused program. steps status the to team Turning is on
software manufacturing completing customer-facing activities. transfer the and finalizing analysis scale-up to and Specifically,
take coming Based this the launch We products we before to line, weeks. upon expect platinum that expect to and time to the and in begin complete over activities start end the instrument shipping QX. year the orders remaining internal of
of excited capabilities our about instrument next-generation our We customers the technology. and the sequencing of are partnering to the to launch demonstrate with upcoming platinum look forward protein
Earlier facilities. sciences technology that Finally, to Haven, hub to I in life year, a we to signed and provide Works, a relocating would New an like our Connecticut. lease with be our this headquarters update we would and regards announced Winchester
business move and capital-efficient a and ongoing our thorough with Branford, efforts cost identified decided to this a to fulfill needs space we not Instead, have consistent more we can infrastructure our our grow infrastructure to Following in facility. our review new to Connecticut, where way. a of in structure, have we continue optimize needs
this to to the our and previous additional entire updates. to for investors. to the mentioned in more now over our understands Chief turn expenditures of time get Patrick, discuss out that our is President would business I calls, Officer, our Operating like our call As team earnings
and of my part so, thank to for doing wanted time as Patrick with Patrick? I my during as recently engagement Quantum-Si. support his Before onboarding and most candidate a
